Johnson & Johnson Derivative Instruments, Gain (Loss) Recognized in Income, Net (Deprecated 2013-01-31)
Johnson & Johnson (JNJ) reported Derivative Instruments, Gain (Loss) Recognized in Income, Net (Deprecated 2013-01-31) of -$232.00 million for the 12-month period ending 2012-01-01, per its 10-K filed 2012-02-23.
Discontinued › Income Statement › Other Income
us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeNet · last filed 2012-02-23
- Johnson & Johnson derivative instruments, gain (loss) recognized in income, net (deprecated 2013-01-31) for the quarter ending 2012-01-01 was -$47.00M.
- Johnson & Johnson derivative instruments, gain (loss) recognized in income, net (deprecated 2013-01-31) for the quarter ending 2011-10-02 was -$67.00M.
- Johnson & Johnson derivative instruments, gain (loss) recognized in income, net (deprecated 2013-01-31) for the quarter ending 2011-07-03 was -$40.00M.
- Johnson & Johnson derivative instruments, gain (loss) recognized in income, net (deprecated 2013-01-31) for the quarter ending 2011-04-03 was -$78.00M.
- Johnson & Johnson derivative instruments, gain (loss) recognized in income, net (deprecated 2013-01-31) for fiscal 2012 was -$232.00M.
- Johnson & Johnson derivative instruments, gain (loss) recognized in income, net (deprecated 2013-01-31) for fiscal 2011 was -$288.00M, a 2157.14% decline from fiscal 2010.
- Johnson & Johnson derivative instruments, gain (loss) recognized in income, net (deprecated 2013-01-31) for fiscal 2010 was $14.00M.
| Period end | Derivative Instruments, Gain (Loss) Recognized in Income, Net (Deprecated 2013-01-31) 3 month | Derivative Instruments, Gain (Loss) Recognized in Income, Net (Deprecated 2013-01-31) 6 month | Derivative Instruments, Gain (Loss) Recognized in Income, Net (Deprecated 2013-01-31) 9 month | Derivative Instruments, Gain (Loss) Recognized in Income, Net (Deprecated 2013-01-31) 12 month |
|---|---|---|---|---|
| 2012-01-01 | -$47.00M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-23 | -$114.00M derived: sum of 2 quarters · filed 2012-02-23 | -$154.00M derived: sum of 3 quarters · filed 2012-02-23 | -$232.00M 10-K · filed 2012-02-23 |
| 2011-10-02 | -$67.00M 10-Q · filed 2011-11-08 | -$107.00M derived: sum of 2 quarters · filed 2011-11-08 | -$185.00M 10-Q · filed 2011-11-08 | -$287.00M derived: sum of 4 quarters · filed 2012-02-23 |
| 2011-07-03 | -$40.00M 10-Q · filed 2011-08-09 | -$118.00M 10-Q · filed 2011-08-09 | -$220.00M derived: sum of 3 quarters · filed 2012-02-23 | -$310.00M derived: sum of 4 quarters · filed 2012-02-23 |
| 2011-04-03 | -$78.00M 10-Q · filed 2011-05-10 | -$180.00M derived: sum of 2 quarters · filed 2012-02-23 | -$270.00M derived: sum of 3 quarters · filed 2012-02-23 | -$324.00M derived: sum of 4 quarters · filed 2012-02-23 |
| 2011-01-02 | -$102.00M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-23 | -$192.00M derived: sum of 2 quarters · filed 2012-02-23 | -$246.00M derived: sum of 3 quarters · filed 2012-02-23 | -$288.00M 10-K · filed 2012-02-23 |
| 2010-10-03 | -$90.00M 10-Q · filed 2011-11-08 | -$144.00M derived: sum of 2 quarters · filed 2011-11-08 | -$186.00M 10-Q · filed 2011-11-08 | -$196.00M derived: sum of 4 quarters · filed 2011-11-08 |
| 2010-07-04 | -$54.00M 10-Q · filed 2011-08-09 | -$96.00M 10-Q · filed 2011-08-09 | -$106.00M derived: sum of 3 quarters · filed 2011-08-09 | -$126.00M derived: sum of 4 quarters · filed 2011-08-09 |
| 2010-04-04 | -$42.00M 10-Q · filed 2011-05-10 | -$52.00M derived: sum of 2 quarters · filed 2011-05-10 | -$72.00M derived: sum of 3 quarters · filed 2011-05-10 | -$53.00M derived: sum of 4 quarters · filed 2011-05-10 |
| 2010-01-03 | -$10.00M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-25 | -$30.00M derived: sum of 2 quarters · filed 2011-02-25 | -$11.00M derived: sum of 3 quarters · filed 2011-02-25 | $14.00M 10-K · filed 2011-02-25 |
| 2009-09-27 | -$20.00M 10-Q · filed 2010-11-10 | -$1.00M derived: sum of 2 quarters · filed 2010-11-10 | $24.00M 10-Q · filed 2010-11-10 | |
| 2009-06-28 | $19.00M 10-Q · filed 2010-08-11 | $44.00M 10-Q · filed 2010-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |